Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;27(10):2040-2046.
doi: 10.1038/leu.2013.93. Epub 2013 Mar 29.

mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells

Affiliations

mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells

F Guo et al. Leukemia. 2013 Oct.

Abstract

Hematopoietic stem/progenitor cells (HSPCs) function to give rise to mature blood cells. Effective DNA damage response (DDR) and maintenance of genomic stability are crucial for normal functioning of HSPCs. Mammalian target of rapamycin (mTOR) integrates signals from nutrients and growth factors to control protein synthesis, cell growth, survival and metabolism, and has been shown to regulate DDR in yeast and human cancer cells through the p53/p21 signaling cascade. Here, we show that gene targeting of mTOR in HSPCs causes a defective DDR due to a variety of DNA damage agents, mimicking that caused by deficient FANCD2, a key component of the Fanconi anemia (FA) DDR machinery. Mechanistically, mTOR(-/-) HSPCs express drastically reduced FANCD2. Consistent with these genetic findings, inactivation of mTOR in human lymphoblast cells by pp242 or Torin 1, mTOR kinase inhibitors, suppresses FANCD2 expression and causes a defective DDR that can be rescued by reconstitution of exogenous FANCD2. Further mechanistic studies show that mTOR deficiency or inactivation increases phosphorylation and nuclear translocation of nuclear factor (NF)-κB, which results in an enhanced NF-κB binding to FANCD2 promoter to suppress FANCD2 expression. Thus, mTOR regulates DDR and genomic stability in hematopoietic cells through a noncanonical pathway involving NF-κB-mediated FANCD2 expression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
mTOR deficiency leads to defective DDR. (a) Western blotting of mTOR protein in bone marrow cells. (bd) DDR of mTOR −/− and mTOR+/+ Lin cells in vitro. Lin cells were stimulated with or without melphalan (0.3 mg/ml). After 16 h, gH2AX foci formation was visualized by immunofluorescence and quantified (c). The images are representative of at least 30 cells (c). The percentage of positive cells (X6 gH2AX foci) was assessed from 30–50 nuclei (c). Damaged DNA was visualized by comet assay, and olive tail moment in at least 50 cells was calculated (d). After 48 h, the apoptotic cells were measured by FACS analysis of annexin V+ cells (b). (e) DDR of mTOR −/− and mTOR+/+ Lin cells in vivo. Mice were injected i.p. with MMC (1 mg/kg body weight) and killed after 72 h. Lin cells were isolated and analyzed for damaged DNA by comet assay. (f) p53 activity in mTOR −/− and mTOR+/+ Lin cells. Phospho- and total p53 in Lin cells was detected by Western blot. Data are represented as mean±s.d. **P<0.01.
Figure 2
Figure 2
FANCD2 deficiency recapitulated DDR phenotypes of mTOR deficiency. (a) Quantitative RT-PCR analysis of FANCD2 expression in LSK cells. (b) Quantitative RT-PCR analysis of FANCA, FANCC, ATM and ATR expression in LSK cells. (c, d) DDR of FNACD2 −/− and FANCD2+/+ Lin cells in vitro. Lin cells were stimulated with or without melphalan (0.3 μg/ml). After 16 h, damaged DNA was visualized by comet assay, and olive tail moment in at least 50 cells was calculated (c). After 48 h, the apoptotic cells were measured by FACS analysis of annexin V+ cells (d). (e) DDR of FNACD2 −/− and FANCD2+/+ Lin cells in vivo. Mice were injected i.p. with MMC (1 mg/kg body weight) and killed after 72 h. Lin cells were isolated and analyzed for damaged DNA by comet assay. Data are represented as mean±s.d. *P<0.05; **pP<0.01.
Figure 3
Figure 3
mTOR inhibition mimics FANCD2 deficiency with defective DDR in human cells. (a, b) FANCD2 expression in human cells upon mTOR inhibition. (a) Human JY B lymphoblasts (Hu-FANCD2+/+) were treated overnight with or without mTOR kinase inhibitor pp242 (2.4 μM) (left) or Torin 1 (100 nM) (right) and analyzed by quantitative RT-PCR for FANCD2 expression. (b) Hu-FANCD2+/+ cells, human Fanconi anemia patient-derived PD20 cells deficient for FANCD2 (Hu-FANCD2 −/− ), and FANCD2-reconstituted Hu-FANCD2 −/− cells (Hu-FANCD2 −/− / FANCD2) were preincubated with or without pp242 for 1 h and then cultured overnight in the presence or absence of MMC (100 ng/ml). The cells were subjected to western blotting for FANCD2 and phopho-S6K. Topo1 was blotted as a loading control. Ub-FANCD2: ubiquitinized FANCD2. (c, d) DDR of Hu-FANCD2+/+ cells after a treatment with pp242 and/or MMC. (e, f) Chromosome breaks and radial formation of Hu-FANCD2+/+ cells after a treatment with pp242 and/or MMC. Hu-FANCD2+/+ cells were preincubated with or without pp242 for 1 h and then cultured for 2 days in the presence or absence of MMC. Chromosomes were then subjected to cytogenetic analysis. A total of 50 cells from each sample were examined and scored. Arrowheads point to chromosome breaks in the Hu-FANCD2+/+ + MMC cells or to radial structures in the Hu-FANCD2+/+ + MMC + pp242 cells. As too many breaks were observed in Hu-FANCD2+/+ + MMC + pp242 cells, the number of chromosome breaks per cell in these cells was artificially set to 10. (g) DDR of Hu-FANCD2 −/− and Hu-FANCD2−/− /FANCD2 cells after a treatment with pp242 and/or MMC. Data are represented as mean±s.d. *P<0.05; **P<0.01.
Figure 4
Figure 4
NF-κB mediates mTOR-dependent FANCD2 expression. (a) Western blotting of phospho- and total NF-κB p65 and p50 in Lin cells. (b) Western blotting of phospho- and total NF-κB p65 in whole-cell extracts (WCE), cytosolic and nuclear fractions of Hu-FANCD2+/+ cells treated overnight with or without pp242 (2.4 μM) (left) or Torin 1 (100 nM) (right). (c) Electrophoretic mobility shift assay (EMSA) on DNA binding activity of NF-κB to canonical, as well as four FANCD2-specific NF-κB consensus sites by using pp242-treated Hu-FANCD2+/+ cells (upper). Supershift assays were performed to determine the binding specificity of NF-κB by using NF-κB-specific antibodies against p65 or p50 (lower). NF-1 DNA binding activity was assayed as a control. (d) Left hand panel: western blotting of phospho- and total NF-κB p65 in Lin cells treated overnight with or without NF-κB inhibitor JSH-23 (10 μM). Right hand panel: quantitative RT-PCR analysis of FANCD2 expression in JSH-23-treated Lin cells. (e) Left hand panel: western blotting of phospho-NF-κB p65 in Lin cells treated overnight with or without NF-κB inhibitory peptide NEMO (15 μM) or control peptide (15 μM). Right hand panel: quantitative RT-PCR analysis of FANCD2 expression in NEMO-treated Lin cells. (f) Left hand panel: western blotting of phospho- and total NF-κB p65 in NF-κB p65+/+ (WT) and NF-κB p65 −/− MEFs treated for 12 h with or without pp242. Middle panel: western blotting of phospho- and total IKKα in IKKα+/+ (WT) and IKKα −/− MEFs treated for 12 h with or without pp242. Right hand panel: quantitative RT-PCR analysis of FANCD2 expression in pp242-treated MEFs. Data are represented as mean±s.d. **P<0.01.

Similar articles

Cited by

References

    1. Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt FW. DNA repair, genome stability, and aging. Cell. 2005;120:497–512. - PubMed
    1. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39–85. - PubMed
    1. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–283. - PubMed
    1. Milyavsky M, Gan OI, Trottier M, Komosa M, Tabach O, Notta F, et al. A distinctive DNA damage response in human hematopoietic stem cell reveals an apoptosis-independent role of p53 in self-renewal. Cell Stem Cell. 2010;7:186–197. - PubMed
    1. Mohrin M, Bourke E, Alexander D, Warr MR, Barry-Holson K, Beau MM, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell. 2010;7:174–185. - PMC - PubMed

Publication types

MeSH terms

Substances